Total Payments
$105,568
2024 Payments
$3,467
Companies
80
Transactions
1,118
Medicare Patients
4,800
Medicare Billing
$6.3M
Payment Breakdown by Category
Other$52,614 (49.8%)
Consulting$31,306 (29.7%)
Food & Beverage$19,038 (18.0%)
Travel$2,100 (2.0%)
Education$509.91 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $38,575 | 18 | 36.5% |
| Consulting Fee | $31,306 | 16 | 29.7% |
| Food and Beverage | $19,038 | 1,039 | 18.0% |
| Honoraria | $10,500 | 3 | 9.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,500 | 2 | 3.3% |
| Travel and Lodging | $2,100 | 12 | 2.0% |
| Education | $509.91 | 27 | 0.5% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $38.86 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Mirati Therapeutics, Inc. | $22,032 | 16 | $0 (2023) |
| Philips Electronics North America Corporation | $20,500 | 6 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $8,718 | 26 | $0 (2023) |
| Myovant Sciences Inc. | $7,670 | 6 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $5,709 | 125 | $0 (2024) |
| PFIZER INC. | $4,210 | 65 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $3,603 | 2 | $0 (2021) |
| F. Hoffmann-La Roche AG | $3,104 | 5 | $0 (2018) |
| Regeneron Healthcare Solutions, Inc. | $3,063 | 8 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,051 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,467 | 49 | Daiichi Sankyo Inc. ($2,374) |
| 2023 | $37,772 | 184 | Mirati Therapeutics, Inc. ($22,032) |
| 2022 | $10,486 | 101 | Philips Electronics North America Corporation ($3,500) |
| 2021 | $22,093 | 70 | Myovant Sciences Inc. ($7,670) |
| 2020 | $4,641 | 75 | Takeda Pharmaceuticals U.S.A., Inc. ($2,869) |
| 2019 | $3,597 | 208 | Merck Sharp & Dohme Corporation ($641.96) |
| 2018 | $10,111 | 218 | Boehringer Ingelheim Pharmaceuticals, Inc. ($6,908) |
| 2017 | $13,401 | 213 | E.R. Squibb & Sons, L.L.C. ($4,269) |
All Payment Transactions
1,118 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/17/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY, TECVAYLI | Food and Beverage | In-kind items and services | $21.93 | General |
| Category: Oncology | ||||||
| 06/05/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,410.00 | General |
| 06/05/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $940.00 | General |
| 05/02/2024 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $31.16 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 03/28/2024 | ABBVIE INC. | LUPRON DEPOT (Drug) | Food and Beverage | In-kind items and services | $19.98 | General |
| Category: ENDOCRINOLOGY | ||||||
| 03/14/2024 | Celgene Corporation | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $36.80 | General |
| Category: Oncology | ||||||
| 03/01/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $28.33 | General |
| Category: CELLT | ||||||
| 03/01/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $19.69 | General |
| 02/29/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $27.40 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 02/27/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $30.22 | General |
| 02/27/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $27.25 | General |
| Category: Oncology | ||||||
| 02/27/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $26.31 | General |
| Category: Oncology | ||||||
| 02/27/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.07 | General |
| 02/27/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 02/26/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $25.16 | General |
| Category: ONCOLOGY | ||||||
| 02/22/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: ONCOLOGY | ||||||
| 02/21/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: Oncology | ||||||
| 02/21/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $20.61 | General |
| Category: Rare Disease | ||||||
| 02/20/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $21.74 | General |
| Category: ONCOLOGY | ||||||
| 02/20/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $2.74 | General |
| Category: ONCOLOGY | ||||||
| 02/15/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $26.21 | General |
| Category: ONCOLOGY | ||||||
| 02/14/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $23.12 | General |
| Category: Oncology | ||||||
| 02/13/2024 | Kyowa Kirin, Inc. | Poteligeo (Drug) | Food and Beverage | In-kind items and services | $22.92 | General |
| Category: Monoclonal Antibody | ||||||
| 02/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $20.16 | General |
| 02/09/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $34.83 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 31 | 1,477 | 57,872 | $8.1M | $1.5M |
| 2022 | 26 | 1,080 | 38,564 | $5.6M | $1.1M |
| 2021 | 27 | 1,157 | 55,168 | $7.6M | $1.6M |
| 2020 | 29 | 1,086 | 70,588 | $8.8M | $2.0M |
Total Patients
4,800
Total Services
222,192
Medicare Billing
$6.3M
Procedure Codes
113
All Medicare Procedures & Services
113 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 27 | 26,600 | $4.7M | $1.1M | 24.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 200 | 655 | $321,788 | $95,026 | 29.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 14 | 3,180 | $226,989 | $58,796 | 25.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 256 | 490 | $171,647 | $48,885 | 28.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 107 | 402 | $192,610 | $47,919 | 24.9% |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mg | Office | 2023 | 14 | 3,175 | $839,280 | $41,026 | 4.9% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 44 | 234 | $1.4M | $31,146 | 2.2% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 39 | 16,770 | $113,198 | $22,820 | 20.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 94 | 94 | $56,224 | $16,507 | 29.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 71 | 491 | $26,882 | $6,769 | 25.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 61 | 99 | $23,359 | $5,530 | 23.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 27 | 76 | $17,656 | $4,392 | 24.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 29 | 88 | $9,119 | $2,287 | 25.1% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 14 | 35 | $6,997 | $1,756 | 25.1% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 39 | 54 | $6,182 | $1,648 | 26.7% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 29 | 224 | $8,723 | $1,419 | 16.3% |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | Office | 2023 | 24 | 80 | $5,563 | $1,410 | 25.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 56 | 93 | $4,298 | $1,146 | 26.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 18 | 46 | $4,601 | $1,110 | 24.1% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 16 | 56 | $4,022 | $1,020 | 25.4% |
| J9045 | Injection, carboplatin, 50 mg | Office | 2023 | 19 | 471 | $7,272 | $920.93 | 12.7% |
| J9060 | Injection, cisplatin, powder or solution, 10 mg | Office | 2023 | 22 | 512 | $3,108 | $784.17 | 25.2% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2023 | 15 | 24 | $2,244 | $562.56 | 25.1% |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | Office | 2023 | 59 | 1,790 | $5,800 | $538.81 | 9.3% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 22 | 37 | $1,629 | $421.06 | 25.8% |
About Dr. Michael Kosty, M.D
Dr. Michael Kosty, M.D is a Hematology & Oncology healthcare provider based in La Jolla, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801857099.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Kosty, M.D has received a total of $105,568 in payments from pharmaceutical and medical device companies, with $3,467 received in 2024. These payments were reported across 1,118 transactions from 80 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($38,575).
As a Medicare-enrolled provider, Kosty has provided services to 4,800 Medicare beneficiaries, totaling 222,192 services with total Medicare billing of $6.3M. Data is available for 4 years (2020–2023), covering 113 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location La Jolla, CA
- Active Since 03/29/2006
- Last Updated 07/10/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1801857099
Products in Payments
- KRAZATI (Drug) $22,032
- (9494) consulting service (Device) $14,000
- LIBTAYO (Biological) $6,776
- (8334) IGT_D Peripheral (Device) $6,500
- ORGOVYX (Drug) $6,158
- OPDIVO (Biological) $5,268
- XTANDI (Drug) $3,651
- TECENTRIQ (Biological) $3,222
- ALUNBRIG (Drug) $2,878
- GILOTRIF (Drug) $2,673
- KEYTRUDA (Biological) $2,200
- Trodelvy (Drug) $1,725
- ENHERTU (Biological) $1,110
- Lenvima (Drug) $750.57
- Cabometyx (Drug) $470.48
- TAGRISSO (Drug) $415.67
- CYRAMZA (Drug) $331.76
- IBRANCE (Drug) $304.28
- ERLEADA (Drug) $274.91
- DARZALEX (Biological) $255.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in La Jolla
Dr. Alan Saven, M.d, M.D
Hematology & Oncology — Payments: $568,420
Hematology & Oncology $568,420
Dimitrios Tzachanis, M.d, M.D
Hematology & Oncology — Payments: $124,180
Hematology & Oncology $124,180
Miss. Erin Roesch, M.d, M.D
Hematology & Oncology — Payments: $70,949
Hematology & Oncology $70,949
Rebecca Shatsky, M.d, M.D
Hematology & Oncology — Payments: $40,806
Hematology & Oncology $40,806
Sonia Ali, M.d, M.D
Hematology & Oncology — Payments: $33,304
Hematology & Oncology $33,304
Sabina Wallach, M.d, M.D
Hematology & Oncology — Payments: $32,820
Hematology & Oncology $32,820